Difference between revisions of "Adrenocortical carcinoma - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "/fulltext " to " ") |
Warner-admin (talk | contribs) m (Text replacement - "https://www.thelancet.com/journals/lanonc/article/PII" to "https://doi.org/10.1016/") |
||
| Line 14: | Line 14: | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
| − | |[https:// | + | |[https://doi.org/10.1016/S1470-2045(15)70081-1 Fassnacht et al. 2015 (GALACCTIC)] |
|2009-2011 | |2009-2011 | ||
|style="background-color:#1a9851"|Phase 3 (C) | |style="background-color:#1a9851"|Phase 3 (C) | ||
| Line 24: | Line 24: | ||
===References=== | ===References=== | ||
| − | # '''GALACCTIC:''' Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. Epub 2015 Mar 18. [https:// | + | # '''GALACCTIC:''' Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. Epub 2015 Mar 18. [https://doi.org/10.1016/S1470-2045(15)70081-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25795408 PubMed] NCT00924989 |
[[Category:Adrenocortical carcinoma regimens]] | [[Category:Adrenocortical carcinoma regimens]] | ||
Revision as of 20:06, 16 September 2022
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main adrenocortical carcinoma page for current regimens.
Recurrent, locally advanced, or metastatic disease
Placebo
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Fassnacht et al. 2015 (GALACCTIC) | 2009-2011 | Phase 3 (C) | Linsitinib | Did not meet primary endpoint of OS Median OS: 356 vs 323 days |
No active antineoplastic treatment.
References
- GALACCTIC: Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. Epub 2015 Mar 18. link to original article PubMed NCT00924989